Cargando…

The effectiveness of high dose zinc acetate lozenges on various common cold symptoms: a meta-analysis

BACKGROUND: A previous meta-analysis found that high dose zinc acetate lozenges reduced the duration of common colds by 42%, whereas low zinc doses had no effect. Lozenges are dissolved in the pharyngeal region, thus there might be some difference in the effect of zinc lozenges on the duration of re...

Descripción completa

Detalles Bibliográficos
Autores principales: Hemilä, Harri, Chalker, Elizabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359576/
https://www.ncbi.nlm.nih.gov/pubmed/25888289
http://dx.doi.org/10.1186/s12875-015-0237-6
_version_ 1782361435669528576
author Hemilä, Harri
Chalker, Elizabeth
author_facet Hemilä, Harri
Chalker, Elizabeth
author_sort Hemilä, Harri
collection PubMed
description BACKGROUND: A previous meta-analysis found that high dose zinc acetate lozenges reduced the duration of common colds by 42%, whereas low zinc doses had no effect. Lozenges are dissolved in the pharyngeal region, thus there might be some difference in the effect of zinc lozenges on the duration of respiratory symptoms in the pharyngeal region compared with the nasal region. The objective of this study was to determine whether zinc acetate lozenges have different effects on the duration of common cold symptoms originating from different anatomical regions. METHODS: We analyzed three randomized trials on zinc acetate lozenges for the common cold administering zinc in doses of 80–92 mg/day. All three trials reported the effect of zinc on seven respiratory symptoms, and three systemic symptoms. We pooled the effects of zinc lozenges for each symptom and calculated point estimates and 95% confidence intervals (95% CI). RESULTS: Zinc acetate lozenges shortened the duration of nasal discharge by 34% (95% CI: 17% to 51%), nasal congestion by 37% (15% to 58%), sneezing by 22% (−1% to 45%), scratchy throat by 33% (8% to 59%), sore throat by 18% (−10% to 46%), hoarseness by 43% (3% to 83%), and cough by 46% (28% to 64%). Zinc lozenges shortened the duration of muscle ache by 54% (18% to 89%), but there was no difference in the duration of headache and fever. CONCLUSIONS: The effect of zinc acetate lozenges on cold symptoms may be associated with the local availability of zinc from the lozenges, with the levels being highest in the pharyngeal region. However our findings indicate that the effects of zinc ions are not limited to the pharyngeal region. There is no indication that the effect of zinc lozenges on nasal symptoms is less than the effect on the symptoms of the pharyngeal region, which is more exposed to released zinc ions. Given that the adverse effects of zinc in the three trials were minor, zinc acetate lozenges releasing zinc ions at doses of about 80 mg/day may be a useful treatment for the common cold, started within 24 hours, for a time period of less than two weeks. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12875-015-0237-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4359576
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43595762015-03-15 The effectiveness of high dose zinc acetate lozenges on various common cold symptoms: a meta-analysis Hemilä, Harri Chalker, Elizabeth BMC Fam Pract Research Article BACKGROUND: A previous meta-analysis found that high dose zinc acetate lozenges reduced the duration of common colds by 42%, whereas low zinc doses had no effect. Lozenges are dissolved in the pharyngeal region, thus there might be some difference in the effect of zinc lozenges on the duration of respiratory symptoms in the pharyngeal region compared with the nasal region. The objective of this study was to determine whether zinc acetate lozenges have different effects on the duration of common cold symptoms originating from different anatomical regions. METHODS: We analyzed three randomized trials on zinc acetate lozenges for the common cold administering zinc in doses of 80–92 mg/day. All three trials reported the effect of zinc on seven respiratory symptoms, and three systemic symptoms. We pooled the effects of zinc lozenges for each symptom and calculated point estimates and 95% confidence intervals (95% CI). RESULTS: Zinc acetate lozenges shortened the duration of nasal discharge by 34% (95% CI: 17% to 51%), nasal congestion by 37% (15% to 58%), sneezing by 22% (−1% to 45%), scratchy throat by 33% (8% to 59%), sore throat by 18% (−10% to 46%), hoarseness by 43% (3% to 83%), and cough by 46% (28% to 64%). Zinc lozenges shortened the duration of muscle ache by 54% (18% to 89%), but there was no difference in the duration of headache and fever. CONCLUSIONS: The effect of zinc acetate lozenges on cold symptoms may be associated with the local availability of zinc from the lozenges, with the levels being highest in the pharyngeal region. However our findings indicate that the effects of zinc ions are not limited to the pharyngeal region. There is no indication that the effect of zinc lozenges on nasal symptoms is less than the effect on the symptoms of the pharyngeal region, which is more exposed to released zinc ions. Given that the adverse effects of zinc in the three trials were minor, zinc acetate lozenges releasing zinc ions at doses of about 80 mg/day may be a useful treatment for the common cold, started within 24 hours, for a time period of less than two weeks. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12875-015-0237-6) contains supplementary material, which is available to authorized users. BioMed Central 2015-02-25 /pmc/articles/PMC4359576/ /pubmed/25888289 http://dx.doi.org/10.1186/s12875-015-0237-6 Text en © Hemila and Chalker; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Hemilä, Harri
Chalker, Elizabeth
The effectiveness of high dose zinc acetate lozenges on various common cold symptoms: a meta-analysis
title The effectiveness of high dose zinc acetate lozenges on various common cold symptoms: a meta-analysis
title_full The effectiveness of high dose zinc acetate lozenges on various common cold symptoms: a meta-analysis
title_fullStr The effectiveness of high dose zinc acetate lozenges on various common cold symptoms: a meta-analysis
title_full_unstemmed The effectiveness of high dose zinc acetate lozenges on various common cold symptoms: a meta-analysis
title_short The effectiveness of high dose zinc acetate lozenges on various common cold symptoms: a meta-analysis
title_sort effectiveness of high dose zinc acetate lozenges on various common cold symptoms: a meta-analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359576/
https://www.ncbi.nlm.nih.gov/pubmed/25888289
http://dx.doi.org/10.1186/s12875-015-0237-6
work_keys_str_mv AT hemilaharri theeffectivenessofhighdosezincacetatelozengesonvariouscommoncoldsymptomsametaanalysis
AT chalkerelizabeth theeffectivenessofhighdosezincacetatelozengesonvariouscommoncoldsymptomsametaanalysis
AT hemilaharri effectivenessofhighdosezincacetatelozengesonvariouscommoncoldsymptomsametaanalysis
AT chalkerelizabeth effectivenessofhighdosezincacetatelozengesonvariouscommoncoldsymptomsametaanalysis